tag horizon-therapeutics 
Pharmaceutical Technology
APRIL 5, 2023
But access to these treatments continues to remain limited due to high price tags and variable availability across regions. More broadly however, several advancements are on the horizon for cell and gene therapies in 2023.
European Pharmaceutical Review
DECEMBER 27, 2023
Studies have since demonstrated significantly reduced CAR-associated CRS and other toxicities without jeopardising therapeutic yield and outcomes; 9 both G-CSF and tocilizumab are now part of daily practice in CART-cell therapy. This is in addition to its considerable price tag.
Expert insights. Personalized for you.
59 
Let's personalize your content